Benny Wong, MD
Hematology & Oncology · East Syracuse, NYNPI 1568676831
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.2%), speaking fees and education — rather than concentrated in one kind of arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 23.3%. Reporting peaked in 2020 at $376 and has fallen 96.5% since, to $13 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 13 payments — averaging $82.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$250
- E.r. Squibb & Sons, L.L.C.$247
- AbbVie$208
- Athenex Pharmaceutical Division, LLC$175
- Johnson & Johnson$123
- Welch Allyn$34
- plus $37 from 3 others
What the payments were for
- Speaking & faculty fees$42540%
- Food & beverage$47544%
- Education$14013%
- Gifts$343%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $250 |
| E.r. Squibb & Sons, L.L.C. | 4 | $247 |
| AbbVie(2 entities) | 2 | $208 |
| Athenex Pharmaceutical Division, LLC | 1 | $175 |
| Johnson & Johnson | 1 | $123 |
| Welch Allyn | 1 | $34 |
| NEW World Medical,inc. | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,073 in reported general payments places this provider in the 45th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $34,921 |
| VeozahFezolinetant | 12 | $6,212 |
| Tamoxifen Citrate | 12 | $448 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $76 |
| Gabapentin | 17 | $58 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in East Syracuse
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.